GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Aoxing Pharmaceutical Company AOXG · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

$33,471

FY2014FY2026

Net income

−$23,378

FY2014FY2026

Free cash flow

−$102,902

FY2014FY2026

Shareholders' equity

—

FY2014FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2016FY2015FY2014
Revenue$33,471——$32.3m$25.5m$12.7m
Research and development———$3.1m$337,067$569,699
Operating income−$23,138−$7,300−$14,820$6.2m$8.7m−$3.3m
Net income−$23,378$55,238−$14,825$2.1m$5.5m−$8.2m
Diluted earnings per share-0.000.00-0.000.030.08-0.14

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2016FY2015FY2014
Total assets———$56.2m$53.0m$38.1m
Cash and short-term investments———$6.9m$5.4m$2.3m
Total liabilities———$38.2m$43.0m$42.1m
Debt———$25.5m$31.8m$33.4m
Shareholders' equity———$18.1m$10.1m−$4.0m
Shares outstanding381m381m381m76m73m—

Cash flow

Fiscal years

FY2026FY2025FY2024FY2016FY2015FY2014
Cash from operations−$102,902—−$14,825−$534,990$3.0m−$7.7m
Capital spending———−$117,862−$2.7m−$268,922
Free cash flow−$102,902—−$14,825−$652,852$320,441−$8.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$2,884$11,295$17,212$2,080————
Operating income−$1,349$2,000−$11,199−$2,439−$900−$800−$5,600−$1,625
Net income−$11,686$1,947−$11,201−$2,438−$900−$800$56,938−$1,625
Diluted earnings per share-0.000.00-0.00-0.00-0.00-0.000.00-0.00
Total assets——$125,879$125,991————
Cash and short-term investments——$23,829$23,941————
Debt——$102,869$102,180————
Shareholders' equity——−$5,465$5,735————

Growth per year

Compound annual rate

3 years5 years10 years
Revenue——-44.8%
Operating income——-39.2%
Net income——-44.4%

Valuation history

At each fiscal year end

FY2026FY2025FY2024
Price to earnings-37.50.8-0.1
Price to sales26.2——

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return7470%748755%18366%1054%4239%915%2067503%41%-53%-43%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 2-to-1 reverse split · 29 Mar 2010
  • 4-to-1 reverse split · 7 Jul 2006
  • 10-to-1 reverse split · 7 Jun 2005

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.